Evaxion to report Q1 2026 results and business update on May 7, 2026

Evaxion, a clinical-stage TechBio company using AI to develop vaccines, will announce its first quarter 2026 financial results and provide a business update on May 7, 2026, before Nasdaq opens. The company will host a conference call and webcast to present the results and answer questions. Evaxion's AI-Immunology™ platform focuses on creating novel vaccine candidates for cancer and infectious diseases, aiming to address significant medical needs. Investors and interested parties can register to join the live event or access the webcast recording afterward on the company's website.